Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Copenhagen Post1h
Novo shares take another hit after new weight loss figures revealed
The Novo Nordisk drug Wegovy has produced a weight loss of 20.7 percent in a study where the company tested a higher dose, the company wrote in a press release on Friday.In comparison, a dose of the ...
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Yahoo Finance2d
Jim Cramer on Novo Nordisk A/S (NVO): ‘That’s Denmark’s Jugular’
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC's Squawk On The Street ...
EconoTimes10h
Denmark PM Responds to Trump’s Greenland Remarks Amid Geopolitical Tensions
Denmarks Prime Minister Mette Frederiksen has called for a meeting with the nations business leaders after U.S.
devdiscourse1d
Denmark's Diplomatic Push: Navigating Greenland Tensions
Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...
Novo Nordisk, other companies meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...